GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK’s $2.2 billion Zantac settlement today ... largest ever acquisition with a deal to buy Fantech in Australia and New Zealand. Its performance has been boosted by increasing awareness of ...

New Zealand’s banking landscape faces significant changes as new players target different segments, potentially disrupting ...

Enter: “Your Cancer Is Our Challenge,” a new initiative that GSK unveiled Tuesday with an aim of raising awareness of and ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Pacific Trade Invest NZ invites you to an important webinar on the FMCG industry in New Zealand. This will be of great ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...